<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We looked for MDM2 gene amplification and over-expression by Southern and Northern blot analysis in 135 and 66 cases of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, including ALL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mp ids='MP_0005481'>CML</z:mp> in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, CLL, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, <z:chebi fb="1" ids="53412">PLL</z:chebi>, non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) and <z:mp ids='MP_0009440'>myeloma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>No amplification of the gene was found </plain></SENT>
<SENT sid="2" pm="."><plain>An over-expression of MDM2 <z:chebi fb="40" ids="33697">RNA</z:chebi> was seen in 9/66 (14%) patients tested, including 3/9 ALL, 3/24 AML, 2/4 <z:mp ids='MP_0009440'>myelomas</z:mp>, 1/1 PLL, but 0/2 <z:mp ids='MP_0005481'>CML</z:mp>, 0/2 NHL and 0/21 MDS </plain></SENT>
<SENT sid="3" pm="."><plain>None of the patients over-expressing MDM2 had modifications of P53 gene transcript or p53 mutations </plain></SENT>
<SENT sid="4" pm="."><plain>Most of the patients over-expressing MDM2 gene had poor prognostic features (including 'unfavourable' cytogenetic abnormalities), poor response to chemotherapy and short survival </plain></SENT>
<SENT sid="5" pm="."><plain>Our findings suggest that over-expression of MDM2 is seen in a relatively small number of <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e>, and is associated with poor prognosis </plain></SENT>
</text></document>